This is a study to test the safety and effectiveness of an investigational chemotherapy agent in men with advanced prostate cancer. After a subject meets all entry criteria and signs informed consent he will be enrolled in the study. Participants will be required to attend regular clinic visits to receive study medication and have their status monitored. They will also be required to have PSA levels measured multiple times throughout the study. A detailed explanation can be provided by the investigator conducting this study.

Condition	Treatment or Intervention	Phase
Prostate Cancer	Drug: ET-743 (YONDELIS)	Phase II

Genders Eligible for Study:  Male

Criteria

• Male subjects with adenocarcinoma of the prostate
• Radiographically documented metastatic disease
• PSA > 15 ng/ml
• Performace status ECOG 0,1 or 2
• Adequate bone marrow reserves, hapatic function, and renal function

Massachusetts
      Massachusetts General Hospital, Boston,  Massachusetts,  02114-2617,  United States; Recruiting

Study ID Numbers:  ET-B-025-02
Record last reviewed:  June 2004
Record first received:  November 7, 2003
ClinicalTrials.gov Identifier:  NCT00072670
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2004-11-10